Evidence map›Paper›PMID 34995482›Full record

ArticleCell2022

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.

Wilfredo F Garcia-Beltran, Kerri J St Denis, Angelique Hoelzemer, Evan C Lam, Adam D Nitido, Maegan L Sheehan, Cristhian Berrios, Onosereme Ofoman, Christina C Chang, Blake M Hauser and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 742 papers.

0numbers the graph read from it
0cells of the map it votes in
742citing papers in PubMed
108.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

742 citing papers in PubMed, 1,086 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

682 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Wilfredo F Garcia-BeltranDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: wgarciabeltran@mgh.harvard.edu.
Kerri J St DenisRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Angelique HoelzemerFirst Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Site Hamburg-Lübeck-Borstel-Riems, Germany; Research Department Virus Immunology, Leibniz Institute for Experimental Virology, Hamburg, Germany.
Evan C LamRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Adam D NitidoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
Maegan L SheehanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Cristhian BerriosDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Onosereme OfomanDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Christina C ChangAlfred Hospital, Central Clinical School, Monash University, Victoria 3181, Australia; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.
Blake M HauserRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Jared FeldmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
Alex L RoedererRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Ph.D. Program in Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA 02115, USA.
David J GregoryVaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Pediatric Infectious Disease, Massachusetts General Hospital for Children, Boston, MA 02114, USA.
Mark C PoznanskyVaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
Aaron G SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Vivek NaranbhaiCenter for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Alejandro B BalazsRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USMassachusetts General Hospital · USHarvard University · USCentre for the AIDS Programme of Research in South Africa · ZALeibniz Institute of Virology (LIV) · DE

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Epitope focusing using structure-based immunogen design approachesF30AI160908 · NIAID · HARVARD MEDICAL SCHOOL · PI HAUSER, BLAKE MARIE · 2021 to 2023
$91k
NIAID NIH HHS F30 AI160908NIAID NIH HHS R01 AI146779NIAID NIH HHS T32 AI007245NIDA NIH HHS DP2 DA040254NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild-type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that received their primary series recently (<3 months), distantly (6-12 months), or an additional "booster" dose, while accounting for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinees. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron, only 4-6-fold lower than wild type, suggesting enhanced cross-reactivity of neutralizing antibody responses. In addition, we find that Omicron pseudovirus infects more efficiently than other variants tested. Overall, this study highlights the importance of additional mRNA doses to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.

Indexed as

breadthCOVID-19Deltainfectivityneutralizing antibodiesOmicronSARS-CoV-2spikevaccinationvariants

Identifiers

PMID34995482
PMCPMC8733787
OpenAlexW4225982774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.